Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

This study is comparing two treatment approaches for newly diagnosed acute myeloid leukemia (AML) — a blood cancer — to determine whether a gentler pill-and-injection combination (venetoclax plus azacitidine) works as well as or better than traditional intensive chemotherapy, particularly for patients who may not tolerate aggressive treatment. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with AML (confirmed by bone marrow or blood test showing 20% or more abnormal cells) - You have not received prior treatment for AML **You may NOT be eligible if...** - You have received prior chemotherapy for AML - You have certain genetic markers that require a different treatment approach - You have severe organ problems that prevent participation Talk to your doctor to see if this trial is right for you.